The absence of validated correlates of protection (CoPs) hampers the rational design and
clinical development of new tuberculosis vaccines. In this review, we provide an overview of …

Mounting evidence indicates that antibodies can contribute towards control of tuberculosis
(TB). However, the underlying mechanisms of humoral immune protection and whether …

In its myriad devastating forms, Tuberculosis (TB) has existed for centuries, and humanity is
still affected by it. Mycobacterium tuberculosis (M. tuberculosis), the causative agent of TB …

Background Tuberculosis (TB) is a leading cause of death worldwide from a single
infectious agent. In China the most common extra-pulmonary TB (EPTB) is pleural …

Delivering novel antimycobacterial agents through the pulmonary route using nanoparticle-
based systems shows promise for treating diseases like tuberculosis. However, creating dry …

Abstract IgG4-related disease (IgG4-RD) is an immune disorder characterized by organ
enlargement and fibrosis leading to functional impairment. Key immune cell subsets …

The importance of humoral immunity in combating TB has gained extensive recognition. In
this study, a subunit vaccine named Ag85A-LpqH (AL) was prepared by fusing the antigen …

Tuberculosis (TB) remains a prominent global health challenge, with the World Health
Organization documenting over 1 million annual fatalities. Despite the deployment of the …

Antibodies have been shown to provide protection against tuberculosis (TB). It is important
to identify the qualitative and quantitative protective effects of antibodies before a clinical …

Development of an effective tuberculosis (TB) vaccine has been challenged by incomplete
understanding of specific factors that provide protection against Mycobacterium tuberculosis …